Spotlight On... J&J chief shells out $9M for Manhattan condo; J&J goes to court over talcum powder cancer claims; Soaring injectable insulin prices shock patients; and more...

Johnson & Johnson ($JNJ) CEO Alex Gorsky and his wife have a new Manhattan pad. The Gorskys laid out $9 million--more than the asking price--for a condo on Riverside Drive, the New York Post reports. The J&J chief recently caught fire for his pay package from an activist investor; in 2014, his compensation amounted to $24.99 million, putting him 8th on FiercePharma's highest-paid list. J&J's headquarters is in New Brunswick, NJ. Story | More | CEO pay ranking

@FiercePharma: Stem cell therapy developed to treat dental disease in cats could also help people. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Teva is adding 20 jobs at UK plant, but only after cutting 80 as it looks for different skills. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa. Report from FiercePharmaMarketing | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) has begun trial Tuesday over claims its talcum powder gave some women cancer. Report

> Prices for injectable insulins have soared over the past few years, leaving patients surprised and frustrated. More

> Drug companies around the world are funneling money into programs aimed at improving patient adherence. More

> India's Aurobindo Pharma has won an FDA green light to market its Isosulfan Blue Injection, 1%, which is used in lymphography procedures. Report

Medical Device News

@FierceMedDev: Next 'blow up' for Theranos? The company's latest legal hire: NYT. Article | Follow @FierceMedDev

@EmilyWFierce: Come for a story about stem cell therapy in felines. Stay for a pic of Bob the cat. More from FierceAnimalHealth | Follow @EmilyWFierce

> ViaCyte acquires J&J IP to further its quest to treat diabetes using implanted stem cells. Story

> Abbott snags CE mark for continuous glucose monitor for kids. Article

> Dx Digest: Illumina inks four genetic research deals; Trovagene makes moves in liquid biopsy with additional coverage for tests. Report

Biotech News

@FierceBiotech: FierceBiotech Radio on Gilead's wide-open future, biotech's long winter and Sanofi's ongoing makeover. More/Subscribe | Follow @FierceBiotech

@JohnCFierce: ICYMI: Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging. Article | Follow @JohnCFierce

> J&J goes all in with ViaCyte, hands over BetaLogics assets in hunt for diabetes cure. Story

> Twist Bio's hard-charging CEO hit by claims she stole Agilent's trade secrets. Report

> InflaRx starts preparation for PhIIb septic organ dysfunction trial after clearing safety study. Article

CRO News

> Onyx Scientific expands again as GMP demand grows. Article

> Catalent invests more in Asia, beefing up a Singapore supply outpost. More

> Fox Foundation backs Evotec's Parkinson's project. Report

> French CRO Novasep bulks up its manufacturing services in the U.S. Story

> BioClinica launches new research offering for marketed meds. Article

Pharma Manufacturing News

> Pakistani man charged with bringing counterfeit drugs into U.S. Report

> Ipca's small-scale API producer in U.K. expanding. Story

> Sanofi commits to developing Zika vax while other big players will evaluate. Item

> Valeant's Bausch + Lomb recalls more than 1M bottles of eye med. More

> Sanofi says job cuts in France should not involve plant closures. Article

Pharma Asia News

> Japan's Daiichi Sankyo joins clinical trial data request system. News

> Pfizer's busy Q4 in emerging markets a prelude for the big show. More

> BeiGene comes in at top end of range in Nasdaq IPO, raising $158.4M. Report

> Asia included in Zika virus warning zone as drugmakers ponder vaccines. Story

> GSK's CEO says it's 'difficult to understand how company is doing.' Article

And Finally... Sen. Ted Cruz (R-TX) wants to change the way the FDA approves new meds. More

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.